NVAX
Novavax IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.37B
P/E Ratio
3.10
EPS
$2.72
Beta
2.65
52W High
$11.97
52W Low
$5.35
50-Day MA
$9.29
200-Day MA
$8.04
Dividend Yield
—
Profit Margin
39.20%
Forward P/E
2.58
PEG Ratio
1.32
About Novavax Inc
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
Fundamentals
| Revenue (TTM) | $1.12B |
| Gross Profit (TTM) | $713.62M |
| EBITDA | $590.85M |
| Operating Margin | 14.20% |
| Return on Equity | -898.00% |
| Return on Assets | 25.70% |
| Revenue/Share (TTM) | $6.93 |
| Book Value | $-0.79 |
| Price-to-Book | 33.20 |
| Price-to-Sales (TTM) | 1.22 |
| EV/Revenue | 0.684 |
| EV/EBITDA | 1.56 |
| Quarterly Earnings Growth (YoY) | -38.10% |
| Quarterly Revenue Growth (YoY) | 66.60% |
| Shares Outstanding | $162.94M |
| Float | $140.47M |
| % Insiders | 4.95% |
| % Institutions | 70.06% |
Analyst Ratings
Consensus ($13.78 target)
5
Buy1
Hold1
Sell2
Strong SellData last updated: 4/9/2026